No connection

Search Results

NBTX vs UFPT

NBTX
Nanobiotix S.A.
BEARISH
Price
$31.83
Market Cap
$1.54B
Sector
Healthcare
AI Confidence
85%
UFPT
UFP Technologies, Inc.
NEUTRAL
Price
$198.68
Market Cap
$1.53B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
NBTX
--
UFPT
22.71
Forward P/E
NBTX
439.39
UFPT
17.35
P/B Ratio
NBTX
-19.23
UFPT
3.62
P/S Ratio
NBTX
47.36
UFPT
2.54
EV/EBITDA
NBTX
-150.9
UFPT
14.86

Profitability

Gross Margin
NBTX
100.0%
UFPT
28.27%
Operating Margin
NBTX
-196.42%
UFPT
14.1%
Profit Margin
NBTX
-73.52%
UFPT
11.33%
ROE
NBTX
--
UFPT
17.82%
ROA
NBTX
-10.06%
UFPT
9.05%

Growth

Revenue Growth
NBTX
--
UFPT
3.4%
Earnings Growth
NBTX
--
UFPT
6.8%

Financial Health

Debt/Equity
NBTX
--
UFPT
0.36
Current Ratio
NBTX
1.09
UFPT
2.69
Quick Ratio
NBTX
1.05
UFPT
1.45

Dividends

Dividend Yield
NBTX
--
UFPT
--
Payout Ratio
NBTX
0.0%
UFPT
0.0%

AI Verdict

NBTX BEARISH

NBTX exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational instability. The valuation is extreme, with a Price/Sales ratio of 47.36 and a negative Price/Book ratio (-19.23), suggesting the company is trading on speculative future catalysts rather than current assets or earnings. While the stock has seen a massive 1-year price surge of 855.9% and maintains a 'strong_buy' analyst consensus, the deterministic data reveals a company with negative equity and unsustainable margins. The disconnect between the technical momentum and the underlying financial decay presents a high-risk profile.

Strengths
Exceptional 1-year price performance (+855.9%)
Strong analyst consensus (Strong Buy)
Consistent earnings surprises (3/4 quarters beat estimates)
Risks
Critical financial health (Piotroski F-Score 2/9)
Extreme valuation (Forward P/E of 439.39 and P/S of 47.36)
Negative shareholders' equity (Price/Book of -19.23)
UFPT NEUTRAL

UFPT exhibits exceptional fundamental health with a perfect Piotroski F-Score of 9/9 and a very conservative debt profile. However, the stock is currently trading at a significant premium, with a current price of $198.68 well above its Graham Number ($104.01) and Intrinsic Value ($150.50). While the earnings track record is stellar, organic growth is sluggish at 1.5%, and high customer concentration (45.8% from two clients) presents a systemic risk. The combination of a high PEG ratio (3.80) and bearish insider activity suggests the stock is currently overvalued despite its operational excellence.

Strengths
Perfect Piotroski F-Score (9/9) indicating peak financial health
Strong liquidity with a Current Ratio of 2.69 and low Debt/Equity of 0.36
Exceptional earnings track record with consistent beats over 25 quarters
Risks
Severe customer concentration: Intuitive Surgical and Stryker account for 45.8% of sales
Weak organic growth (1.5%) suggesting reliance on acquisitions for top-line expansion
High valuation relative to growth (PEG Ratio of 3.80)

Compare Another Pair

NBTX vs UFPT: Head-to-Head Comparison

This page compares Nanobiotix S.A. (NBTX) and UFP Technologies, Inc. (UFPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile